CHE vs LFST stock comparison
Chemed vs. LifeStance Health Group · data as of November 13, 2026
Chemed (CHE) has a market value of about $7.1B, LifeStance Health Group (LFST) about $5.4B. Over their latest twelve months Chemed had revenue of $2.7B and LifeStance Health Group $1.7B.
On our five checks Chemed scores higher: 2.4 out of 5 (weak) against 1.8 (weak).
By area, the stronger company is LifeStance Health Group on future growth; Chemed on track record; Chemed on financial health; Chemed on shareholder returns.
Chemed is cheaper on earnings (P/E 26.3 vs. 74.1), while LifeStance Health Group grew revenue faster over five years (46.3% vs. 4.0% a year).
Chemed leads on 16 of the compared lines and LifeStance Health Group on 5.
Side by side
| CHE | LFST | |
|---|---|---|
| Size and price | ||
| Market cap | $7.1B | $5.4B |
| Share price | $548.20 | $14.08 |
| Score | ||
| Overall score (of 5) | 2.4 | 1.8 |
| Value | 0 | 0 |
| Future growth | 0 | 3 |
| Track record | 3 | 1 |
| Financial health | 5 | 4 |
| Shareholder returns | 4 | 1 |
| Valuation | ||
| P/E (TTM) | 26.3 | 74.1 |
| Forward P/E | 20.0 | 33.3 |
| Price / free cash flow | 24.1 | 29.9 |
| Price / sales | 2.7 | 3.2 |
| EV / EBITDA | 17.1 | 37.9 |
| PEG | — | 6.58 |
| DCF value vs. price | −7% | −63% |
| Business | ||
| Revenue | $2.7B | $1.7B |
| Net income | $282M | $72M |
| Free cash flow | $295M | $179M |
| Net margin | 10.6% | 4.3% |
| Gross margin (5-yr avg.) | 35.0% | — |
| ROIC (5-yr avg.) | 23.7% | -6.9% |
| Growth | ||
| Revenue growth (1 yr) | 4.1% | 13.9% |
| Revenue growth (5 yrs, per year) | 4.0% | 46.3% |
| EPS growth (5 yrs, per year) | -1.2% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$344M | -$259M |
| Dividend yield | 0.51% | None |
| Shareholder yield | 6.6% | 0.0% |
| Analysts | ||
| Upside to average target | +13% | +19% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: CHE TTM to September 30, 2026, LFST TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Chemed or LifeStance Health Group?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Chemed scores 2.4 out of 5 and LifeStance Health Group 1.8; the table shows where each one is stronger.
Is Chemed cheaper than LifeStance Health Group?
On trailing earnings, Chemed trades at a P/E of 26.3 and LifeStance Health Group at 74.1, so Chemed is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Chemed or LifeStance Health Group?
Over five years LifeStance Health Group grew revenue about 46.3% a year and Chemed about 4.0% a year.
Which pays a higher dividend?
Chemed yields 0.51% and LifeStance Health Group nothing (no dividend).
Full Chemed analysis → Full LifeStance Health Group analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.